Non-small cell lung cancer: the era of targeted therapy

Mara B Antonoff, Jonathan D&#39;CunhaDivision of Thoracic and Foregut Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USAAbstract: In this review, the authors aim to provide an overview of current molecular targeted therapies for NSCLC, to propose an algorithm for c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antonoff MB, D&#39;Cunha J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/63dfbe897d0d4446b74983840e262549
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:63dfbe897d0d4446b74983840e262549
record_format	dspace
spelling	oai:doaj.org-article:63dfbe897d0d4446b74983840e2625492021-12-02T04:47:39ZNon-small cell lung cancer: the era of targeted therapy1179-2728https://doaj.org/article/63dfbe897d0d4446b74983840e2625492012-07-01T00:00:00Zhttp://www.dovepress.com/non-small-cell-lung-cancer-the-era-of-targeted-therapy-a10284https://doaj.org/toc/1179-2728Mara B Antonoff, Jonathan D&#39;CunhaDivision of Thoracic and Foregut Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USAAbstract: In this review, the authors aim to provide an overview of current molecular targeted therapies for NSCLC, to propose an algorithm for clinical application of presently available treatment strategies, and to identify future directions for this important area of research. Historically, choice of treatment algorithm for the management of non-small cell lung cancer (NSCLC) has relied heavily upon histology and clinical staging information, typically assigning patients to surgery, chemotherapy, radiation, or a combination thereof. However, previous treatment strategies have been fraught with disappointing response rates and significant systemic toxicities. The concept of personalized therapy for NSCLC involves characterization of each individual patient&#39;s tumor, in terms of genetic aberrations and expected biologic behavior, and using this information to tailor subsequent clinical management. Several driver mutations have been identified to date in subsets of patients with NSCLC, and, by focusing on specific molecular targets, new agents have been developed with the intent of treating the cancer cells while causing minimal toxicity to benign, healthy cells. In particular, current strategies exist to identify patients with epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase rearrangements, with promising results upon clinical application of agents targeting these abnormalities. Moving forward, attempts are being made to determine comprehensive genetic and biologic characterization of individuals&#39; NSCLC tumors and to incorporate these findings into everyday practice. The era of targeted therapy is upon us. As we seek to expand our knowledge of the specific molecular and cellular derangements leading to growth and proliferation of NSCLC tumors, our efforts bring us closer to ultimately providing each patient with a personalized plan of care.Keywords: personalized therapy, algorithm, EGFR, ALK, KRASAntonoff MBD&#39;Cunha JDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 31-41 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Antonoff MB D&#39;Cunha J Non-small cell lung cancer: the era of targeted therapy
description	Mara B Antonoff, Jonathan D&#39;CunhaDivision of Thoracic and Foregut Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USAAbstract: In this review, the authors aim to provide an overview of current molecular targeted therapies for NSCLC, to propose an algorithm for clinical application of presently available treatment strategies, and to identify future directions for this important area of research. Historically, choice of treatment algorithm for the management of non-small cell lung cancer (NSCLC) has relied heavily upon histology and clinical staging information, typically assigning patients to surgery, chemotherapy, radiation, or a combination thereof. However, previous treatment strategies have been fraught with disappointing response rates and significant systemic toxicities. The concept of personalized therapy for NSCLC involves characterization of each individual patient&#39;s tumor, in terms of genetic aberrations and expected biologic behavior, and using this information to tailor subsequent clinical management. Several driver mutations have been identified to date in subsets of patients with NSCLC, and, by focusing on specific molecular targets, new agents have been developed with the intent of treating the cancer cells while causing minimal toxicity to benign, healthy cells. In particular, current strategies exist to identify patients with epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase rearrangements, with promising results upon clinical application of agents targeting these abnormalities. Moving forward, attempts are being made to determine comprehensive genetic and biologic characterization of individuals&#39; NSCLC tumors and to incorporate these findings into everyday practice. The era of targeted therapy is upon us. As we seek to expand our knowledge of the specific molecular and cellular derangements leading to growth and proliferation of NSCLC tumors, our efforts bring us closer to ultimately providing each patient with a personalized plan of care.Keywords: personalized therapy, algorithm, EGFR, ALK, KRAS
format	article
author	Antonoff MB D&#39;Cunha J
author_facet	Antonoff MB D&#39;Cunha J
author_sort	Antonoff MB
title	Non-small cell lung cancer: the era of targeted therapy
title_short	Non-small cell lung cancer: the era of targeted therapy
title_full	Non-small cell lung cancer: the era of targeted therapy
title_fullStr	Non-small cell lung cancer: the era of targeted therapy
title_full_unstemmed	Non-small cell lung cancer: the era of targeted therapy
title_sort	non-small cell lung cancer: the era of targeted therapy
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/63dfbe897d0d4446b74983840e262549
work_keys_str_mv	AT antonoffmb nonsmallcelllungcancertheeraoftargetedtherapy AT damp39cunhaj nonsmallcelllungcancertheeraoftargetedtherapy
_version_	1718401008789356544

Non-small cell lung cancer: the era of targeted therapy

Ejemplares similares